Strengthening colonoscopy screening in primary care: A preventive imperative before the coming surge.

Introduction
India’s cancer landscape is changing in quiet but consequential ways. As the nation moves through its demographic, and epidemiologic transition, the balance of disease is tilting steadily toward noncommunicable causes. Cardiovascular disorders, diabetes, and cancers now account for most of the adult morbidity and mortality, a shift accelerated by urbanization, dietary change, and population aging. Within this expanding spectrum, Colorectal cancer (CRC) has remained curiously underrecognized: significant enough to trouble oncologists, yet absent from the country’s preventive health agenda.
The reasons for this invisibility are both statistical and perceptual. India’s current age-standardized CRC incidence rates, 2.4 per 100,000 for colon and 2.2 per 100,000 for rectum, appear modest compared with Western figures exceeding 20 per 100,000.[1] This apparent reassurance has, paradoxically, delayed policy attention. But as life expectancy increases and dietary patterns converge with those of industrialized nations, these low rates are giving way to rapid growth. GLOBOCAN 2022 data already estimate nearly 65,000 new colorectal cancers annually, and projections indicate that the burden will double by 2050, driven almost entirely by demographic expansion rather than changing individual risk.[1]
What makes this trajectory especially concerning is that CRC is one of the few major cancers that can be prevented. The adenoma–carcinoma sequence unfolds slowly over a decade or more, offering a long window for intervention. Effective screening, through colonoscopy or stool-based testing, can interrupt this process entirely. Yet, unlike breast or cervical cancer, CRC has no place in India’s national screening framework. The result is a widening “colonoscopy gap:” a growing population at risk, and an endoscopic infrastructure insufficient to meet even present diagnostic demand.
Against this backdrop, understanding the current and future burden of CRC is no longer an academic exercise. It is a public health imperative. The following section explores how this preventable disease is silently gaining ground in India, and what lessons can be drawn from nations that have successfully curbed its toll.

The Silent Emergence of a Preventable Cancer
CRC occupies a peculiar position in India’s public health consciousness, present enough to concern oncologists, yet invisible enough to escape primary-care priorities. According to GLOBOCAN 2022 data, India recorded 34,046 new colon cancer cases, and 30,817 rectal cancers, with age-standardized rates of 2.4 and 2.2 per 100,000, respectively.[1] These figures pale in comparison to Western nations, where rates exceed 20 per 100,000.[1] Yet this statistical comfort obscures a more troubling reality: India’s CRC burden is set to explode.
Unlike many malignancies, CRC offers a remarkable preventive opportunity. The disease typically evolves over 10–15 years from benign adenomatous polyps, a window during that colonoscopy detection, and removal can interrupt the malignant cascade entirely.[2] This is not merely early detection; it is primary prevention. The United States demonstrates this principle vividly: despite an aging population and persistently high incidence rates, CRC mortality has plateaued and even declined since widespread colonoscopy adoption in the early 2000s. Between 2018 and 2023, the U.S. recorded approximately 308,000 colon cancer deaths, but modeling studies suggest this number would have been 40%–50% higher without systematic screening [Figure 1].[3]
The contrast with India is stark. Here, CRC remains a disease diagnosed late, treated expensively, and survived poorly. Most patients present at stage III or IV, when cure rates plummet, and treatment costs skyrocket. The question is no longer whether screening works. Decades of international evidence have settled that debate,[4] but whether India will implement it before the coming demographic wave overwhelms an already strained oncology infrastructure.

Current Indian Epidemiological Landscape
India’s current CRC statistics, approximately 70,000 new cases and 41,000 deaths in 2022, might suggest a manageable problem. This perception is dangerous. Population projections indicate a 101% increase in CRC incidence and 110% rise in mortality by 2050, driven primarily by aging demographics and lifestyle transitions [Figure 2].[1] India’s population aged 60, and above will nearly triple from 140 million today to over 340 million by mid-century. Since CRC incidence rises exponentially after age 50, this demographic shift alone guarantees a crisis.[1]
The gender dimension warrants attention. Males account for approximately 60% of both incidence and mortality, likely reflecting higher rates of tobacco use, alcohol consumption, and dietary factors. This disparity suggests that risk-factor modification, and targeted screening could yield disproportionate benefits in men, a lesson worth heeding as programs are designed.[1]
Current mortality rates, while lower than Western nations in absolute terms, reflect late diagnosis rather than superior outcomes. Stage-for-stage survival in India lags high-income countries, hampered by treatment delays, incomplete surgical access, and limited adjuvant therapy availability. In essence, India faces CRC mortality from two directions: rising incidence and suboptimal treatment outcomes. Screening addresses both by reducing disease burden and shifting diagnosis toward earlier, more curable stages. Figure 3 shows the sex disparity in Colon and Rectal Cancer incidence and mortality.

Comparative Perspective: Lessons from High-Income Nations
The United States offers both a cautionary tale and a roadmap. American CRC incidence remains high, among the world’s highest, yet mortality has declined substantially over three decades. The Centers for Disease Control and Prevention data reveal that colon cancer deaths occur overwhelmingly after age 50, with peak mortality between 65 and 85 years [Figure 5].[5] This age distribution mirrors India’s emerging demographic profile, and underscores the urgency of establishing screening before the elderly population expands further. While U.S. CRC mortality has declined with screening adoption, India has not experienced a similar reduction [Figure 4].
What transformed the U.S. trajectory was not novel therapeutics but systematic screening.[6] Colonoscopy uptake reached approximately 70% of the eligible population by the 2010s, accompanied by fecal occult blood testing and, more recently, fecal immunochemical tests (FIT).[7] The result: an estimated 30%–35% mortality reduction attributable primarily to early detection and polypectomy. Importantly, this success occurred despite rising obesity rates, processed food consumption, and other CRC risk factors—demonstrating that screening can overcome adverse lifestyle trends.
Other high-income nations achieved similar results through varied approaches. Countries like Japan and South Korea implemented population-wide stool testing with colonoscopy referral for positive results, achieving high participation through organized, government-led programs.[8] European nations adopted flexible sigmoidoscopy or colonoscopy at defined ages, often with single-screen protocols proving effective.[9] The lesson is not that one method is superior, but that systematic, accessible, sustained screening, regardless of modality, and saves lives.
India cannot simply replicate Western models, given resource constraints, and healthcare infrastructure differences.[10] However, the fundamental biology of CRC progression remains identical across populations. Polyps take years to transform into cancer; this timeline is the same whether the patient lives in Mumbai or Manhattan. India’s challenge is adapting proven interventions to its unique context, not reinventing the preventive Figure 4 shows the colon cancer mortality trends in India vs the USA.

The Missed Opportunity in India’s Primary-Care Framework
India has demonstrated capacity for large-scale cancer screening. The National Programmed for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) screening for oral, breast, and cervical cancers, diseases where early detection improves outcomes.[11] Oral cancer screening through visual inspection, Pap smear programs, and mammography initiatives have reached millions, albeit with variable coverage and quality.
Yet CRC screening remains conspicuously absent from this framework. The reasons are multiple: Perceived low incidence, competing health priorities, limited endoscopy infrastructure, and insufficient primary-care physician awareness. Each excuse carries some validity; collectively, they constitute a policy failure.
Consider the economic argument alone. Late-stage CRC treatment involves surgery, chemotherapy, radiation, prolonged hospitalization, and palliative care, costs that can devastate families even with insurance coverage. A colonoscopy costs a fraction of stage III treatment and, when polyps are removed, prevents cancer entirely. Health economic analyses from diverse settings consistently show CRC screening to be cost-effective or even cost-saving over 10–15-year horizons. India’s growing middle class, increasingly covered by health insurance, represents an ideal target population where screening investment would yield rapid returns.
Primary-care physicians are natural gatekeepers for screening, yet most lack training in CRC risk stratification and patient counseling. Medical curricula emphasize late-stage disease management over preventive gastroenterology. Even patients who present with concerning symptoms, rectal bleeding, anemia, altered bowel habits, often undergo incomplete evaluation due to physician discomfort with colonoscopy referral or patient reluctance. Normalizing CRC discussion in primary care, akin to hypertension or diabetes screening, is essential.
Access remains a critical barrier. Urban tertiary hospitals have colonoscopy facilities, but district-level availability is sparse. Training gastroenterologists and surgical endoscopists takes years, and equipment costs are substantial. However, stool-based testing, FIT in particular, offers a bridge solution.[1213] FIT kits are inexpensive, can be deployed through primary health centers, and have sensitivity approaching 80% for advanced adenomas and cancer. Positive results trigger colonoscopy referral, concentrating endoscopic resources on high-yield cases. This tiered approach balances accessibility and resource efficiency.
Public awareness lags even further behind infrastructure. While breast cancer awareness has grown through advocacy and celebrity campaigns, CRC remains stigmatized, associated with bowel habits that polite society avoids discussing. Educational campaigns must destigmatize colorectal health and normalize screening as routine preventive care, no different from blood pressure checks or cholesterol testing.

Survivorship and Secondary Prevention: Beyond the First Diagnosis
Screening’s benefits extend beyond preventing incident cancers. Surveillance epidemiology and end results (SEER) data from the United States reveal that colorectal cancer survivors face substantial long-term risks. The data from deceased patients with CRC shows that, approximately 84% did develop a second primary malignancy during their lifetime, with lung cancer being most common, followed by additional primary colorectal cancers. This pattern reflects both shared risk factors, particularly tobacco, and treatment effects, including radiation-induced malignancies.[14] Additionally, SEER data show that most CRC survivors die from causes other than the index cancer, including cardiovascular disease and second primaries [Figure 6].
More surprisingly, only 23.6% of deaths in CRC survivors are attributable to the original colorectal cancer. Cardiovascular disease, respiratory diseases, and other cancers account for the majority. This mortality spectrum underscores that CRC survivorship care cannot focus narrowly on recurrence monitoring but must address holistic health maintenance.
For India, these findings have immediate implications. Post-treatment surveillance requires not just colonoscopy follow-up, but integrated management of tobacco use, obesity, diabetes, and cardiovascular risk factors, conditions increasingly prevalent in India’s urbanizing population. Primary-care physicians must view CRC survivors as high-risk patients requiring comprehensive preventive care, not simply discharged oncology cases.
Secondary prevention, preventing subsequent cancers in survivors also argues for extending screening beyond the initial diagnosis. Metachronous colon cancers (new primary tumors arising separately from the original) occur in 3%–5% of patients, necessitating lifelong surveillance colonoscopy. Family members of CRC patients carry elevated risk and merit earlier, more intensive screening. Identifying and counselling these high-risk groups represents low-hanging fruit in CRC prevention.[14]

The Path Forward: Policy and Practice Recommendations
This mismatch between rising CRC risk and inadequate screening capacity has been conceptualized as the “colonoscopy gap” in India [Figure 7]. India’s CRC screening strategy must be pragmatic, scalable, and tailored to resource realities while maintaining effectiveness. We propose a tiered implementation framework:
National Policy Integration: CRC screening should be formally incorporated into NPCDCS or the Ayushman Bharat Health and Wellness Centers preventive care package. This provides funding mechanisms, standardized protocols, and political visibility essential for sustained implementation.

Screening Modalities:

Tier 1 (Population-Wide): Annual or biennial FIT for average-risk individuals aged 50–75 years, deployed through primary health centers, and community health workers. FIT’s simplicity and low cost make it ideal for initial coverage expansion.

Tier 2 (Targeted Colonoscopy): Direct colonoscopy for high-risk groups, those with positive FIT results, family history of CRC, inflammatory bowel disease, or concerning symptoms. This concentrates endoscopic resources on individuals most likely to benefit.

Tier 3 (Opportunistic Urban Screening): In urban centers with adequate endoscopy capacity, offer colonoscopy as a primary screening option for motivated individuals aged 45–75 years, leveraging private-sector infrastructure.

Capacity Building: Medical education must emphasize preventive gastroenterology. Gastroenterology training programs should increase enrollment, and surgical departments should train general surgeons in screening colonoscopy. Non-physician endoscopists—trained nurses or technicians performing screening under physician supervision—represent a viable workforce expansion strategy employed successfully in the United Kingdom.
Quality Assurance: Screening colonoscopy requires rigorous quality metrics—adenoma detection rates, cecal intubation rates, bowel preparation adequacy—to ensure effectiveness. National standards and periodic auditing must accompany program expansion to avoid the dilution of quality that plagues other screening initiatives.
Public Awareness: A national CRC awareness campaign, potentially linked to World Cancer Day or other health observances, should normalize colorectal screening. Messaging should emphasize prevention (not just early detection), simplicity (stool testing), and life-saving potential, drawing parallels to widely accepted mammography, and Pap smears.
Private-Sector Engagement: India’s thriving private healthcare sector should be incentivized—through insurance coverage mandates or tax benefits—to offer guideline-concordant CRC screening. Corporate wellness programs could include FIT testing in executive health checkups, normalizing screening among employed populations.
Research and Monitoring: Establishing a national CRC registry would enable tracking of incidence, mortality, stage distribution, and screening uptake—data essential for program refinement. Research into India-specific risk factors, optimal screening ages for different populations, and cost-effectiveness in local contexts should inform ongoing policy adjustments.

Conclusion: The Coming Decade Defines the Outcome
India’s colorectal cancer burden stands at a tipping point. Current rates, while lower than Western nations, are poised to double within a generation—driven by inexorable demographic aging and accelerating lifestyle transitions toward processed diets, sedentary behavior, and obesity. Without decisive intervention, India will face 140,000 new CRC cases and over 80,000 deaths annually by 2050, overwhelming oncology services, and devastating families financially and emotionally.[1]
Yet 60%–70% of this suffering is preventable. Colonoscopy screening, supplemented by stool-based testing for population reach, offers proven efficacy backed by decades of international evidence. The technology exists, the biology is understood, and the implementation models are available for adaptation. What remains is political will and strategic investment.
The parallel with other screening successes is instructive. India’s pulse polio campaign demonstrated that complex health interventions could reach hundreds of millions through coordinated national effort. Cervical cancer screening, despite incomplete coverage, has saved countless lives and established infrastructure that CRC programs could leverage. The question is not whether India can implement effective CRC screening, but whether it will do so before demographic realities make the task exponentially harder.
Colonoscopy screening is India’s most urgent missed preventive opportunity in cancer control. The coming decade will determine whether India confronts CRC proactively, bending the mortality curve downward through prevention, or reactively, managing an overwhelming burden of advanced disease. For the hundreds of thousands of Indians who will develop colorectal cancer in the next generation, this choice is quite literally a matter of life and death. The time to act is not when the crisis is upon us—it is now, while prevention remains possible.

Conflicts of interest
There are no conflicts of interest.